Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303
Benzinga Newsdesk 2 months ago
NewsInitiationAnalyst RatingsPrice Target
Canaccord Genuity analyst Whitney Ijem initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $303.
Canaccord Genuity analyst Whitney Ijem initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $303.